Literature DB >> 15344605

Treatment of early diffuse cutaneous systemic sclerosis patients in Japan by low-dose corticosteroids for skin involvement.

K Takehara1.   

Abstract

Systemic sclerosis (SSc) is a multiorgan systemic disorder characterized by excessive collagen deposition. This disease is usually classified into two clinical subsets - diffuse cutaneous SSc (dSSc) and limited cutaneous SSc (lSSc). We have proposed low-dose oral corticosteroid treatment with indication criteria consisting of the following three conditions: (1) early onset; (2) edematous changes; and (3) rapid progression. Cases satisfying 2 or 3 criteria have a definite indication, while those meeting 0 or 1 criterion have no indication. We treated 23 cases of dSSc by low-dose oral corticosteroid (prednisolone 20 mg/day as the initial dosage) and evaluated the effect using the modified Rodnan total skin thickness score (m Rodnan TSS). The mean initial TSS (20.3+/-9.3) decreased significantly to 12.8+/-7.0 after one year of treatment (p < 0.005) and to 8.7+/-6.1 at final evaluation (p < 0.001). Thus, we confirmed the usefulness of oral corticosteroid treatment for early dSSc in Japanese patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15344605

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

Review 2.  Corticosteroids and the risk of scleroderma renal crisis: a systematic review.

Authors:  Gerald Trang; Russell Steele; Murray Baron; Marie Hudson
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

3.  A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study.

Authors:  Elena Rezus; Alexandra Maria Burlui; Bogdan Gafton; Teodora Alexa Stratulat; Gabriela Rusu Zota; Anca Cardoneanu; Ciprian Rezus
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

4.  Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis.

Authors:  Takayasu Suzuka; Takuya Kotani; Takashi Saito; Shogo Matsuda; Takako Sato; Tohru Takeuchi
Journal:  Arthritis Res Ther       Date:  2022-10-07       Impact factor: 5.606

5.  Therapeutic efficacy of combined glucocorticoid, intravenous cyclophosphamide, and double-filtration plasmapheresis for skin sclerosis in diffuse systemic sclerosis.

Authors:  Kensuke Suga; Hiroyuki Yamashita; Yuko Takahashi; Daisuke Katagiri; Fumihiko Hinoshita; Hiroshi Kaneko
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.889

6.  Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

Authors:  Ariane L Herrick; Deborah J Griffiths-Jones; W David Ryder; Justin C Mason; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2020-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.